Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ALK gene rearrangements are identified in a small proportion of newly diagnosed patients with NSCLC (approximately 5%).
“ALK gene rearrangements are identified in a small proportion of newly diagnosed patients with NSCLC (approximately 5%).77,87–89”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works
Self-citationMasters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850 · see citing works
ALK inhibitors in the treatment of advanced NSCLC
Gridelli, C., Peters, S., Sgambato, A., Casaluce, F., Adjei, A. A., & Ciardiello, F. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.07.002 · Cited by 180 · see citing works
Self-citationCabillic, F., Gros, A., Dugay, F., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000072 · Cited by 151 · see citing works
ROS1 fusions in Chinese patients with non-small-cell lung cancer
Cai, W., Li, X., Su, C., Fan, L., Zheng, L.-M., Fei, K., Zhou, C., Manegold, C., & Schmid‐Bindert, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt071 · Cited by 86 · see citing works
“3% [23].”
Conde, E., Suárez‐Gauthier, A., Benito, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107200 · Cited by 66 · see citing works
Complex renal cysts associated with crizotinib treatment
Schnell, P., Bartlett, C. H., Solomon, B., Tassell, V. R., Shaw, A. T., Pas, T. M. D., Lee, S. D., Lee, G. K., Tanaka, K., Tan, W., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.437 · Cited by 61 · see citing works
Liu, L., Xu, Q., Cheng, L., Chun-hu, M., XIAO, L., Xu, D., Gao, Y., Wang, J., & Song, H. (2014) · Oncology Letters · doi:10.3892/ol.2014.2721 · Cited by 38 · see citing works
Caccese, M., Ferrara, R., Pilotto, S., Carbognin, L., Grizzi, G., Caliò, A., Brunelli, M., Cuppone, F., Petraglia, S., Scarpa, A., et al. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1242578 · Cited by 27 · see citing works
Carrera, P. M., & Ormond, M. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.04.008 · Cited by 17 · see citing works
D’Arcangelo, M., Wynes, M. W., & Hirsch, F. R. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835d8175 · Cited by 11 · see citing works
“005), whereas FISH positivity seemed to affect neither RFS nor OS [31].”
BackgroundCeritinib for Treatment of ALK-Rearranged Advanced Non-Small-Cell Lung Cancer
Vansteenkiste, J. (2014) · Future Oncology · doi:10.2217/fon.14.94 · Cited by 11 · see citing works
Yu, H., Liu, M., Qiu, H., & Yang, K. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.10.006 · Cited by 10 · see citing works
Targeted therapies in medical oncology: successes, failures and next steps
Mallarkey, G., & Coombes, R. C. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012467829 · Cited by 11 · see citing works
ALK Testing in Non-Small Cell Lung Carcinoma: What Now?
Kerr, K. M. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000171 · Cited by 9 · see citing works
Self-citationPrognostic factors in resected lung carcinomas
Kerr, K. M., & Nicolson, M. C. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.023 · Cited by 8 · see citing works
“[107] Blackhall F, Peters S, Kerr KM, et al.”
BackgroundSelf-citationPrabu, D. S. D., Lakshmanan, S., Ramalakshmi, N., et al. (2019) · Synthetic Communications · doi:10.1080/00397911.2018.1554144 · Cited by 6 · see citing works
Viala, M., Brosseau, S., Planchard, D., et al. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.02.016 · Cited by 6 · see citing works
Lakshmanan, S., Govindaraj, D., Mahalakshmi, K., et al. (2021) · Structural Chemistry · doi:10.1007/s11224-020-01707-5 · Cited by 5 · see citing works
Understanding lung cancer molecular subtypes
Pender, A., & Popat, S. (2014) · Clinical Practice · doi:10.2217/cpr.14.39 · Cited by 4 · see citing works
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
Berghmans, T., Remmelink, & Awada, A. H. (2012) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s12959 · Cited by 2 · see citing works
“7% if only IHC 3+ was considered.(30) IHC could be viewed as a screening test with a high negative predictive value.”
- Authors
- Blackhall, F., Peters, S., Kerr, K. M., O'Byrne, K., Hager, H., Sejda, A., Soltermann, A., Dooms, C., Felip, E., Marchetti, A., Speel, E.-J. M., Price, N., Savic, S., de Jong, J., Martorell, M., Thunnissen, E., Bubendorf, L., Dafni, O., Rosell, R., & Stahel, R. A.
- Affiliations
- The Christie Hospital (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- Aberdeen Royal Infirmary (GB)
- St. James's Hospital (IE)
- Aarhus University Hospital (DK)
- Gdańsk Medical University (PL)
- University Hospital Zurich (CH)
- Universitair Ziekenhuis Leuven (BE)
- Vall d'Hebron Hospital Universitari (ES)
- University of Chieti-Pescara (IT)
- University Hospital of Basel (CH)
- Universitat de València (ES)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Frontier Science Foundation-Hellas (GR)
- Institut Català d'Oncologia (ES)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 23
- Pages
- ix73
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3023973085
- Cited by
- 21
- References
- 0
- Citations by year
- 2021: 1 · 2019: 1 · 2018: 1 · 2016: 1 · 2015: 4 · 2014: 6 · 2013: 6 · 2012: 1
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- ALK rearrangement, non-small cell lung cancer, ALK-positive lung adenocarcinoma, prevalence, immunohistochemistry, H-score, clinicopathological features, clinical outcomes, resected lung cancer, smoking status, sex differences, molecular subtyping, prognostic factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
